Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
03 Ottobre 2023 - 8:00AM
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the
“Company”), announces four presentations on additional analyses
from its successful Phase 3 ENHANCE studies with ensifentrine for
the treatment of chronic obstructive pulmonary disease (“COPD”)
will be presented at CHEST Annual Meeting (“CHEST”) 2023. The data
are published in the CHEST Annual Meeting on-line supplement.
Ensifentrine is Verona Pharma’s investigational dual PDE3 and PDE4
inhibitor, a potential first-in-class product currently under
review by the US FDA for the maintenance treatment of COPD.
The presentations will include pooled analyses
from the ENHANCE-1 and ENHANCE-2 studies which demonstrated
treatment with ensifentrine resulted in substantial reductions in
the rate and risk of COPD exacerbations regardless of recent
exacerbation history and was well-tolerated. In addition, the
presentations will include subgroup data analyses which demonstrate
improvements in lung function, symptoms, quality of life endpoints
and reductions in the rate and risk of exacerbations regardless of
background therapy as well as reduction in daily rescue medication
use.
Frank Sciurba, MD, Associate Professor of
Medicine at the University of Pittsburgh School of Medicine
commented: “These additional analyses from the ENHANCE program
further demonstrate ensifentrine’s potential, if approved, to
become an effective novel treatment for COPD patients.
Ensifentrine’s combined bronchodilator and non-steroidal
anti-inflammatory activity could lead to meaningful benefits in a
broad population of COPD patients.
Details of Verona Pharma’s presentations are
listed below and linked to the CHEST website:
Presentation: Ensifentrine, a
novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, reduces
exacerbation rate and risk regardless of exacerbation history in
pooled ENHANCE trial analysesPresenter: Frank
Sciurba, MD, Pulmonary, Allergy and Critical Care Medicine at the
University of Pittsburgh School of
MedicineSession: Latest Advances in Management of
Obstructive Lung Disease
Presentation: Nebulized
ensifentrine improves lung function, symptoms, quality of life and
reduces exacerbations in symptomatic COPD patients regardless of
background LAMA or LABA therapyPresenter: Thomas
Siler, MD, Pulmonary Disease, Saint
CharlesSession: Latest Advances in Management of
Obstructive Lung Disease
Presentation: Ensifentrine
reduces COPD symptoms and rescue medication use over 24 weeks in
two Phase 3 trials in symptomatic patients with moderate to severe
COPDPresenter: Frank Sciurba, MD, Pulmonary,
Allergy and Critical Care Medicine at the University of Pittsburgh
School of MedicineSession: Latest Advances in
Management of Obstructive Lung Disease
Presentation: Pooled safety
results over 24 weeks from the ENHANCE program with ensifentrine, a
novel dual phosphodiesterase (PDE) 3 and 4
inhibitorPresenter: Thomas Siler, MD, Pulmonary
Disease, Saint CharlesSession: Latest Advances in
Management of Obstructive Lung Disease
For further information please contact:
|
|
Verona Pharma plc |
US Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200 |
Victoria Stewart, Senior Director of Investor Relations and
Communications |
IR@veronapharma.com |
Argot PartnersUS Investor Enquiries |
Tel: +1-212-600-1902verona@argotpartners.com |
Ten Bridge CommunicationsInternational / US Media
Enquiries |
Tel: +1-312-523-5016tbcverona@tenbridgecommunications.com |
Leslie Humbel |
|
About Verona Pharma
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for the treatment of chronic respiratory
diseases with significant unmet medical needs. If successfully
developed and approved, Verona Pharma’s product candidate,
ensifentrine, has the potential to become the first non-steroidal
therapy for the treatment of respiratory diseases that combines
bronchodilator and anti-inflammatory activities in one molecule.
The Company has evaluated nebulized ensifentrine in its Phase 3
clinical program ENHANCE (“Ensifentrine as a Novel inHAled
Nebulized COPD thErapy”) for COPD maintenance treatment.
Ensifentrine met the primary endpoint in both ENHANCE-1 and
ENHANCE-2 trials demonstrating statistically significant and
clinically meaningful improvements in lung function. In addition,
ensifentrine substantially reduced the rate and risk of COPD
exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. In
the third quarter of 2023, the US Food and Drug Administration
accepted for review the Company’s NDA for ensifentrine for the
maintenance treatment of patients with COPD and assigned a PDUFA
target action date of June 26, 2024. Two additional
formulations of ensifentrine have been evaluated in Phase 2 trials
for the treatment of COPD: dry powder inhaler (“DPI”) and
pressurized metered-dose inhaler (“pMDI”). Ensifentrine has
potential applications in cystic fibrosis, asthma and other
respiratory diseases. For more information, please visit
www.veronapharma.com
Forward-Looking Statements
This press release contains forward-looking
statements. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements relating to the timing of the FDA’s potential approval
of the NDA for ensifentrine by the PDUFA date of June 26, 2024, or
at any other time, statements regarding the potential for
ensifentrine to be the first novel mechanism available for the
maintenance treatment of COPD in over 10 years, the first therapy
for the treatment of respiratory diseases to combine bronchodilator
and non-steroidal anti-inflammatory activities in one molecule, and
the potential to change the treatment paradigm for COPD patients,
the potential of ensifentrine in the treatment of cystic fibrosis,
asthma and other respiratory diseases, and the potential of the DPI
and pMDI formulations of ensifentrine.
These forward-looking statements are based on
management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from our expectations expressed or implied by the forward-looking
statements, including, but not limited to, the following: our
limited operating history; our need for additional funding to
complete development and commercialization of ensifentrine, which
may not be available and which may force us to delay, reduce or
eliminate our development or commercialization efforts; the
reliance of our business on the success of ensifentrine, our only
product candidate under development; economic, political,
regulatory and other risks involved with international operations;
the lengthy and expensive process of clinical drug development,
which has an uncertain outcome; serious adverse, undesirable or
unacceptable side effects associated with ensifentrine, which could
adversely affect our ability to develop or commercialize
ensifentrine; we may not be successful in developing ensifentrine
for multiple indications; our ability to obtain approval for and
commercialize ensifentrine in multiple major pharmaceutical
markets; misconduct or other improper activities by our employees,
consultants, principal investigators, third-party service providers
and licensees; our inability to realize the anticipated benefits
under licenses granted by us to third parties to develop and
commercialize ensifentrine, our future growth and ability to
compete depends on retaining our key personnel and recruiting
additional qualified personnel; material differences between our
“top-line” data and final data; our reliance on third parties,
including clinical research organizations, clinical investigators,
manufacturers and suppliers, and the risks related to these
parties’ ability to successfully develop and commercialize
ensifentrine; lawsuits related to patents covering ensifentrine and
the potential for our patents to be found invalid or unenforceable;
lawsuits related to our licensing of patents and know-how with
third parties for the development and commercialization of
ensifentrine; changes in our tax rates, unavailability of certain
tax credits or reliefs or exposure to additional tax liabilities or
assessments could affect our profitability, and audits by tax
authorities could result in additional tax payments for prior
periods; and our vulnerability to natural disasters, global
economic factors, geo-political actions and unexpected events,
including health epidemics or pandemics. These and other important
factors under the caption “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2022, as updated in our
Quarterly Reports on Form 10-Q and our other reports filed with the
SEC, could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While we may elect
to update such forward-looking statements at some point in the
future, we disclaim any obligation to do so, even if subsequent
events cause our views to change. These forward-looking statements
should not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Verona Pharma (NASDAQ:VRNA)
Storico
Da Ott 2023 a Ott 2024